PDB30 EVALUATING THE COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 VERSUS HUMAN PREMIX INSULIN FOR THE TREATMENT OFTYPE 2 DIABETES IN A SPANISH SETTING
Abstract
Authors
D Tucker WJ Valentine S Nielsen C Townsend R Kotchie H Scheijbeler